The peptide and Unit 3 capacity utilizations, they were at the lower end of 30% to 40%. Then what was the rationale behind expanding the capacity and putting up capex of INR320 crores, INR350 crores that was announced recently?
That I understood. But what was the rationale for the expansion in either or both cases?
I'm hoping on multiple. Just wanted to have a quick update on a few products that you launched a couple of years ago, if I'm not wrong, NEXLETOL and NEXLIZET. I just wanted to understand where they're at. And also, some questions in terms of how are you planning to launch this product? Do you plan to have any partners? And what would be the size of the opportunity? Just wanted to confirm if it's $7 billion, $8 billion, if you could correct me. And what are the other competitors on this particular product?
No, sir. That was all from my side.